[ASCO 现场]ASCO Highlight:免疫治疗与靶向治疗仍是 2017 热点

2017-06-04 12:26 来源:丁香园

1.png

当地时间 6 月 2 日,吸引了 30000 余名来自世界各地肿瘤学医护人员的 2017 年美国临床肿瘤学会年会(ASCO 2017)在美国芝加哥麦考密克展览中心(McCormick place)正式拉开大幕。

ASC0002.png

ASCO003.png

在"Making a Difference in Cancer Care With You" 的会议主题号召下,共有来自 78 个国家的超过 2150 份摘要将在年会期间进行现场展示,英文阅读能力较强的同学可以直接访问 http://dxy.me/asco,获取最新的 ASCO 官方实时更新的 Oral Abstract Session 重大学术进展。会方在官方发布的新闻中强调到:本届 ASCO 会议将会以免疫治疗与靶向治疗作为学术重点热点,以提升肿瘤预防与治疗的整体水平。

ASCO004.png

4.png

值得国人骄傲的是,随着中国学者在肿瘤临床与科研领域的不断深入与探索,我国不仅拥有吴一龙教授、秦叔逵教授、石远凯教授、陆舜教授等行业领军人物,我国肿瘤研究整体水平的国际地位也在逐渐提升,根据会方在 JCO(Journal of Clinical Oncology)上公布的 Meeting Proceedings 统计,中国学者共计有 8 项重要进展口头汇报、2 项学术进展壁报讨论、77 项学术进展壁报展示。

美国临床肿瘤学会作为以致力于通过研究、教育、预防以及传递优质医疗为使命的肿瘤学专业组织,将全球杰出医学工作者的研究成果在年会上整理、讨论、碰撞,站在会议现场,你将发现肿瘤学的进展正以我们肉眼所不能追赶的速度在向前高速发展。

请继续关注《丁香园》关于 2017 美国临床肿瘤学会年会的各项报道!


附:8 项重要进展口头汇报简介

8500 Oral Abstract Session, Mon

Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104). First Author: Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

Oral Abstract Session, Mon

Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979). First Author: Hu Liang, Sun Yat-Sen University Cancer Center, Guangzhou, China

6005 Oral Abstract Session, Mon

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. First Author: Ming-Yuan Chen, Sun Yat-Sen University Cancer Center, Guangzhou, China

6002 Oral Abstract Session, Mon

A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT). First Author: Anthony T. C. Chan, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, The Chinese University of Hong Kong, Hong Kong, Hong Kong


3508 Oral Abstract Session, Mon

A randomized, double-blind, placebo-controlled, multi-centered phase 3 trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO). First Author: Jin Li, Fudan University Shanghai Cancer Center, Shanghai Medical College, Shanghai, China


LBA3001 Oral Abstract Session, Mon

Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. First Author: Frank (Xiaohu) Fan, Nanjing Legend Biotech, Nanjing, China


LBA9007 Oral Abstract Session, Tue

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. First Author: Tony Mok, Chinese University of Hong Kong, Hong Kong, China


9005 Oral Abstract Session, Tue

CNS response to osimertinib in patients (pts) with T790M-positive advanced NSCLC: Data from a randomized phase III trial (AURA3). First Author: Tony Mok, Chinese University of Hong Kong, Hong Kong, China


编辑: 迟庆媛

网友评论